Introducing MattsonJack's Comorbidity Database™

The new Comorbidity Database™ is designed to help clients make strategic decisions based on an in-depth understanding of the importance of mutually exclusive and overlapping conditions, expanding the potential of pharmaceutical product development.

The new Comorbidity Database™ consists of two modules: Comorbidity Database™ - CNS 2.0, which focuses on mental health disorders, and Comorbidity Database™ - Med 2.0, which features a broad range of medical diagnosis and risk factors, excluding mental health disorders. The modules can be used to help determine the value of order of subsequent indications for currently marketed products. Download a PDF brochure on the Comorbidity Database™.

The Comorbidity Database™ modules works in concert with MattsonJack's Epi Database®, which is considered the gold standard in terms of breadth of countries and depth of indications covered in epidemiology data. The Comorbidity Database™ product offerings exemplify MattsonJack's commitment to epidemiology and continuous product enhancement.

COMORBIDITY DATABASE™ - CNS 2.0

The Comorbidity Database™ - Central Nervous System (CNS) 2.0 allows users to determine the patient population numbers for all possible combinations of the following disorders:

Benefits of Comorbidity Database™ - CNS 2.0

• Define exact patient comorbidity groups for all possible combinations to
  help quantify the size of new opportunities
  
• Patient populations projected through 2025 to help simplify and improve forecasting
  
• Determine the number of prevalent cases in the U.S. of each
  combination of diagnoses to ensure forecasting accuracy

Source data are drawn from the National Comorbidity Replication Survey is a national survey of approximately 10,000 people 18 years and older in the United States. The most recent data available is from the survey conducted in 2001-2002. The survey used a fully structured interview to examine mental health disorders. Included were anxiety disorders, mood disorders, impulse control disorders, and substance use disorders.

• Dyslipidemia
• Asthma
• Congestive Heart Failure (CHF)
• Post Myocardial Infarction (PMI)
• Stroke
• Peripheral Artery Disease (PAD)
• High-Density Lipoproteins (HDL)
• Body Mass Index (BMI)

• C-Reactive Protein (CRP)
• Framingham Score
• Diabetes
  
• Hypertension
  
• Metabolic Syndrome
  
• Angina
  
• Smoking
  
• Low-Density Lipoproteins (LDL)
  
• Triglycerides
  
• Fasting Plasma Glucose (FPG)
  
• Waist Circumference
  
• Total Cholesterol
  
  

Benefits of Comorbidity Database™ - Med 2.0

• Group diseases and/or risk factors based on related diseases for
  a more in depth understanding of market opportunities
• Customize the definitions of risk factors (LDL, HDL, total cholesterol, triglycerides, hypertension, FPG, BMI, and other criteria) to quantify
  the size of the market opportunities
• Determine the number of prevalent cases in the U.S. of each
  combination of diagnoses to ensure forecasting accuracy

Source data are drawn from the National Health and Nutrition Examination Survey (NHANES), a large population-based study that is designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it includes detailed data from household interviews, medical examination, and laboratory analysis. Since 1999, the survey has included over 31,000 respondents.The most recent survey available was conducted in 2003-2004, and included approximately 10,000 respondents.